Is an Orphan Drug's Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness?
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 2, p. 225, doi. 10.1007/s40273-021-01096-5
- By:
- Publication type:
- Article
Works matching IS 11707690 AND DT 2022 AND VI 40 AND IP 2
Results: 8
1
2
Factors Limiting Subgroup Analysis in Cost-Effectiveness Analysis and a Call for Transparency.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 2, p. 149, doi. 10.1007/s40273-021-01108-4
- By:
- Publication type:
- Article
3
How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 2, p. 157, doi. 10.1007/s40273-021-01107-5
- By:
- Publication type:
- Article
4
The Value of Genomic Testing: A Contingent Valuation Across Six Child- and Adult-Onset Genetic Conditions.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 2, p. 215, doi. 10.1007/s40273-021-01103-9
- By:
- Publication type:
- Article
5
Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 2, p. 183, doi. 10.1007/s40273-021-01089-4
- By:
- Publication type:
- Article
6
Future Offspring Costs in Economic Evaluation.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 2, p. 141, doi. 10.1007/s40273-021-01102-w
- By:
- Publication type:
- Article
7
The Utility of a Rapid Review Evaluation Process to a National HTA Agency.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 2, p. 203, doi. 10.1007/s40273-021-01093-8
- By:
- Publication type:
- Article
8
The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 2, p. 233, doi. 10.1007/s40273-021-01090-x
- By:
- Publication type:
- Article